1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled

With data demonstrating superiority to Humira and likely lower pricing than anti-TNF drugs, baricitinib may be poised to make more of an impact than Pfizer has with its JAK inhibitor Xeljanz.

With regulatory filings now under review in the US, EU and Japan for baricitinib, an oral, selective JAK1/2 inhibitor, Eli Lilly & Co. sees a chance to position the drug in the competitive rheumatoid arthritis space after generic methotrexate therapy but before use of tumor necrosis factor inhibitors.

The Indianapolis pharma outlined its strategy for baricitinib, partnered with Incyte Corp., during an investor day presentation May 24 in New York (see related story,Also see "Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms" - Pink Sheet, 30 May, 2016.). Senior Medical Director Bill Macias highlighted the drug's strong data package, derived from five Phase III trials, including data showing superiority to AbbVie Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Smoldering Myeloma Endpoint Questions Carry J&J’s Darzalex Faspro To US FDA AdComm

 
• By Bridget Silverman

The US FDA seeks advice on the clinical meaningfulness of the endpoints of J&J’s AQUILA trial in smoldering multiple myeloma, highlighting the pitfalls of being the first candidate for the precancerous condition.

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

More from North America

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.